SPRY · ARS Pharmaceuticals, Inc.

Current Thesis

ARS Pharmaceuticals' recovery case rests on neffy growth surviving lower commercial spending; the next quarterly report tests that case, and a weekly close below $4.76 invalidates it. Operational confirmation requires US neffy revenue above the $26.2 million reported for Q2 2026 while management maintains its second-half cash expense guidance, published on 2026-08-13. Company results.

The stabilization described in the 2026-08-30 research note has failed: the supplied adjusted close was $4.76 on 2026-09-11, below the previously published $5.76 weekly-close threshold. As an interpretation of the original access-led repricing story, the narrative is dead — the 2026-06-24 disclosure reported no new commercial formulary additions, and the September close remains below that broken threshold. The recovery case is a separate, low-conviction hypothesis about commercial execution.

Since the previous note, ARS announced September investor appearances, including a Cantor fireside chat scheduled for 2026-09-11. That date has elapsed. The company's release index, checked on 2026-09-13, lists the 2026-09-01 conference announcement as its latest release; it supplies no subsequent operating update confirming the recovery hypothesis. Conference announcement, company releases.

Bullish and bearish views on ARS Pharmaceuticals, Inc.

The model's bull view on ARS Pharmaceuticals, Inc. (SPRY), in brief: Revenue provides an operating foothold. US neffy net product revenue reached $26.2 million in Q2 2026, versus $17.5 million in Q1 2026, according to the company's respective results releases. These observations establish sequential growth; the sample is too small to establish… The bear view: The expense reset remains unproven. On 2026-08-13, management guided second-half 2026 cash selling, general and administrative expenses plus research and development expenses to $100–110 million. The same release reported a Q2 net loss of $62.3 million; the forecast expense… Both cases follow in full.

Bull Case

• Revenue provides an operating foothold. US neffy net product revenue reached $26.2 million in Q2 2026, versus $17.5 million in Q1 2026, according to the company's respective results releases. These observations establish sequential growth; the sample is too small to establish its durability. Q2 results, Q1 results.
• Targeted accounts show higher penetration. ARS reported Q2 2026 epinephrine market share of 8% in field-targeted accounts and 5% overall on 2026-08-13. This supports the rationale for concentrating commercial activity on prescribers, but the comparison does not establish that the revised spending plan will preserve growth. Company results.

Bear Case

• The expense reset remains unproven. On 2026-08-13, management guided second-half 2026 cash selling, general and administrative expenses plus research and development expenses to $100–110 million. The same release reported a Q2 net loss of $62.3 million; the forecast expense reduction is not a measured profitability improvement. Company results.
• Management's 2026-08-13 expectation of cash-flow breakeven by end-2027 remains a forecast; a financing announcement or withdrawal of that timetable would undermine the self-funding case. Company results.
• Coverage litigation remains unresolved. Schall, Brown & Schwartz's 2026-09-08 notice identifies a securities lawsuit covering 2026-03-09 through 2026-06-24 and an October lead-plaintiff deadline. The allegations are not adjudicated findings. Law-firm notice.

Setup & Price Structure

The supplied market series records a $4.76 adjusted close on 2026-09-11, a three-month decline of 51.2%, and a price 63.6% below the $13.06 trailing annual high. The 14-period relative strength index was 34.6. These are measured weakness indicators; they do not establish an impending reversal.

The $4.76 reference close defines the prospective recovery test, rather than a demonstrated support shelf. A weekly close below it ends this hypothesis. The earlier $5.76 threshold remains a historical broken level; the available observations are insufficient to establish a new base.

Observable coverage includes a Robbins notice dated 2026-09-02 and a Schall, Brown & Schwartz notice dated 2026-09-08 about the same lawsuit. That is litigation-related coverage clustering, not evidence of expanding speculative participation. Current short interest, fund flows, insider transactions and moving-average distances are missing; no crowding conclusion follows from these notices. Robbins notice, Schall notice.

Catalyst Calendar (next 30 days)

• 2026-10-05 — Lead-plaintiff application deadline. The 2026-09-08 Schall, Brown & Schwartz notice confirms this procedural date. It does not resolve neffy demand, insurance access or the merits of the allegations. Law-firm notice.

No company-confirmed operating catalyst inside the next 30 days was identified in the releases and events pages checked on 2026-09-13. The next quarterly results are the recovery case's operating checkpoint, but their date is unconfirmed; the earlier November estimate is not treated as a scheduled event. Company events.

What Would Change Our Mind

Failure to preserve the September reference close breaks the prospective recovery structure: a weekly close below $4.76, the market's 2026-09-11 adjusted close, invalidates the case. This replaces no historical outcome; the prior $5.76 condition has already been breached.

The operating case would fail if the next quarterly report shows US neffy revenue at or below Q2 2026's $26.2 million, or management raises the second-half 2026 cash expense range above $100–110 million. Conversely, revenue above that Q2 figure with the expense guidance maintained would satisfy the defined operating recovery test, provided the price invalidation has not occurred first. Those thresholds come from the 2026-08-13 results, not an independently estimated revenue forecast. Company results.

Correlation Notes

This is a single-name commercial-execution case. The dated evidence concerns ARS's 2026-08-13 spending reset and its 2026-09-11 price weakness; no paired sector-return series is available to measure biotechnology-market correlation. A sector rally alone would not satisfy the company-specific revenue and expense conditions above.